Great Lakes Advisors LLC Makes New $882,000 Investment in Royalty Pharma PLC $RPRX

Great Lakes Advisors LLC acquired a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 15,726 shares of the biopharmaceutical company’s stock, valued at approximately $882,000.

A number of other large investors have also made changes to their positions in RPRX. LM Advisors LLC acquired a new position in Royalty Pharma in the 4th quarter valued at approximately $26,000. Lloyd Advisory Services LLC. bought a new stake in shares of Royalty Pharma in the 4th quarter worth approximately $30,000. Blue Trust Inc. grew its holdings in shares of Royalty Pharma by 173.4% during the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 437 shares in the last quarter. CIBC Private Wealth Group LLC grew its holdings in shares of Royalty Pharma by 66.4% during the 4th quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 446 shares in the last quarter. Finally, Larson Financial Group LLC increased its position in shares of Royalty Pharma by 31.9% during the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 306 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Citigroup upped their target price on Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Royalty Pharma in a research note on Wednesday, August 12th. The Goldman Sachs Group reissued a “buy” rating and issued a $66.00 price target on shares of Royalty Pharma in a report on Thursday, August 6th. Bank of America restated a “buy” rating on shares of Royalty Pharma in a research note on Wednesday, August 5th. Finally, Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday. Eight research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Royalty Pharma presently has a consensus rating of “Buy” and a consensus target price of $60.86.

Insider Buying and Selling at Royalty Pharma

In other Royalty Pharma news, EVP Marshall Urist sold 9,099 shares of Royalty Pharma stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $55.88, for a total transaction of $508,452.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 150,000 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $54.40, for a total transaction of $8,160,000.00. Following the completion of the sale, the executive vice president owned 559,399 shares in the company, valued at $30,431,305.60. This represents a 21.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 462,596 shares of company stock valued at $25,989,538. 18.84% of the stock is currently owned by company insiders.

Royalty Pharma Trading Up 1.2%

RPRX stock opened at $61.31 on Friday. Royalty Pharma PLC has a 1-year low of $34.08 and a 1-year high of $62.13. The company has a current ratio of 2.80, a quick ratio of 2.80 and a debt-to-equity ratio of 0.88. The business’s 50 day moving average is $57.36 and its 200-day moving average is $51.81. The firm has a market cap of $35.25 billion, a P/E ratio of 42.28, a P/E/G ratio of 1.43 and a beta of 0.43.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.27 by $0.05. The business had revenue of $674.14 million during the quarter, compared to the consensus estimate of $758.93 million. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%. Equities analysts anticipate that Royalty Pharma PLC will post 5.3 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $0.235 per share. This represents a $0.94 annualized dividend and a yield of 1.5%. The ex-dividend date is Friday, August 14th. Royalty Pharma’s dividend payout ratio is currently 64.83%.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.